4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-21-041602
Chief Executive Officer sold 30,000 shares at an average $126.43 ($3,792,804)
- Chief Executive Officer acquired 30,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2021-06-15 | Option exercise | +30,000 | $12.57 | $377,100 | 217,719 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-06-15 | Sale | −10,383 | $125.39 | $1,301,924 | 207,336 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-06-15 | Sale | −16,129 | $126.86 | $2,046,125 | 191,207 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-06-15 | Sale | −3,488 | $127.51 | $444,755 | 187,719 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2021-06-15 | Option exercise · Stock Option (Right to Buy) | −30,000 | 63,333 | D | ||
| Open-market sales · 30,000 sh · avg $126.43 · $3,792,804 | |||||||
Loading xslF345X03/doc4.xml…